Scholar Rock (SRRK) investor relations material

Introduction and purpose

• FDA approved ISEMBYLD (apitegromab-mstn), the first muscle-targeted therapy for SMA, for patients aged two and older on SMN2-targeted treatment, marking a major milestone for the SMA community.

• SMA is a rare neuromuscular disease causing progressive muscle wasting and loss of motor function.

• The approval addresses the unmet need for therapies directly targeting muscle in SMA.

Details of approval or decision

• ISEMBYLD received a broad label, covering all SMA patients two years and older on SMN2-targeted therapy.

• The U.S. launch began immediately after approval, with commercial availability and product shipping within days.

• The recommended dose is 10 mg/kg IV every four weeks.

• A Rare Pediatric Disease Priority Review Voucher was awarded with the approval.

Impact on industry and stakeholders

• The approval redefines the standard of care for SMA, enabling combination approaches targeting both motor neuron and muscle.

• Estimated 6,600 U.S. patients and 35,000 globally are eligible.

• The company is expanding globally, targeting Europe, Japan, and up to 50 countries.

• Dedicated support services are available to assist patients and caregivers with access and logistics.

• Strong financial position with $492M in cash and access to $150M in debt, plus a priority review voucher to monetize.